Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 7Colorectal Neoplasms 4Colonic Neoplasms 2Anus Neoplasms 2Adenomatous Polyposis Coli 2HIV Infections 1Colorectal Adenoma 1Anal Canal Carcinoma 1

Interventions

Fluorouracil 26Radiotherapy 17Mitomycin 17Cisplatin 12Capecitabine 12pembrolizumab 10Cyclophosphamide 9Radiation 8Paclitaxel 8fludarabine 7Specimen Handling 7Nivolumab 7Carboplatin 7Magnetic Resonance Spectroscopy 6Cetuximab 6Biopsy 6Papillomavirus Vaccines 5Drug Therapy 5dehydroftorafur 4aldesleukin 4Vaccines 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Watchful Waiting 3Taxes 3Oxaliplatin 3Observation 3Light Coagulation 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Anus Neoplasms × Sigmoidoscopy × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡